T.Rx Capital

Overview

T.Rx Capital is a venture capital firm focused on early-stage healthcare innovation, investing in companies that apply novel technologies to frontier biology and aim to redefine patient care. The firm closed its inaugural fund, T.Rx Capital Fund I, at $77.5 million in September 2025, with backing from a global base of investors, including institutional allocators, family offices, and high-net-worth individuals across North America, Europe, the Middle East, and Asia. Notable backers include individual founders from Polaris Partners, Lux Capital, Third Rock Ventures, ARCH Venture Partners, and Dr. Robert Langer, who also serves as Executive Chairman of T.Rx Capital. Co-founded by Michael Langer, Dr. Corey McCann, and Dr. Kwesi Frimpong-Boateng, T.Rx Capital has a team of seasoned healthcare investors and operators with backgrounds in creating, funding, scaling, and transacting healthcare companies. The firm aims to build a concentrated portfolio of 10–15 companies, writing $5–$10 million checks and taking active roles in company creation, scale, and governance. T.Rx Capital focuses on early-stage investments across healthcare, with a particular emphasis on biotechnology, techbio, and tech-enabled services. The firm's advisory board includes distinguished leaders in science, medicine, and industry, such as Dr. Bob Langer, Executive Chairman of T.Rx Capital; Dr. Mark Levin, founder of Third Rock Ventures; Dr. Freda Lewis-Hall, former Chief Medical Officer at Pfizer; Dr. John Abele, co-founder of Boston Scientific; Dr. Al Sandrock, CEO of Voyager Therapeutics; and Dr. Peter Barton Hutt, former Chief Counsel of the FDA. T.Rx Capital's investment strategy involves partnering early with scientifically rigorous, execution-focused teams and providing the capital, network, and strategic support to help them build durable value from day one. As of February 2026, T.Rx Capital has not publicly disclosed specific portfolio investments. However, the firm has indicated a focus on techbio startups, next-generation therapeutic modalities, and AI-enabled discovery companies. The firm's name reflects its dual mission: 'Rx' for medicine and 'T' for technology. With its scientific and investment pedigree, T.Rx Capital aims to fill the gap between traditional biotech investing and the growing field of technology-enabled life sciences.

Investment Focus

• Focus on early-stage healthcare companies
• Emphasis on biotechnology, techbio, and tech-enabled services
• Active involvement in company creation, scale, and governance